Sign in

Mirza Faham Ali Baig

Research Analyst at UBS Investment Bank

Mirza Faham Ali Baig is the Global Tobacco Analyst at UBS Investment Bank, specializing in equity research on major tobacco companies worldwide. He covers leading firms such as British American Tobacco, Philip Morris International, Imperial Brands, Swedish Match, and Altria Group, with a performance record including a 52% success rate and notable returns such as a 50.6% gain on Swedish Match. Baig began his career as an analyst and has held his current position in the UBS Research Division for several years, focusing on consumer staples and tobacco sectors. He is professionally active in London and holds recognized financial industry credentials, conducting institutional research coverage for UBS clients.

Mirza Faham Ali Baig's questions to ALTRIA GROUP (MO) leadership

Question · Q3 2025

Mirza Faham Ali Baig questioned the potential financial benefit from duty drawbacks, specifically if it could approximate Altria's federal excise tax payments and drive high single-digit EPS growth towards the mid-single-digit CAGR by 2028. He also asked if the FDA's pilot program for nicotine pouches would influence the national launch of ON+ and why the FDA could accelerate reviews for pouches but not for the larger e-vapor category.

Answer

CEO Billy Gifford cautioned against premature conclusions on duty drawback benefits, framing them as part of a broader international relationship. He stated that Altria's decisions are based on long-term company interests and a functioning regulatory system. Mr. Gifford explained the FDA's pilot program started with nicotine pouches as a 'fairly set category' for learning, with hopes for future expansion to other categories like vapor.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts